menu

ReachMD

Be part of the knowledge.
Register

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now
ReachMD Faculty

Public Profile

Omid Hamid, MD
Omid Hamid, MD

    Omid Hamid, MD is the Director of the Melanoma Center at The Angeles Clinic and Research Institute. Dr. Hamid works to ensure that patients receive access to the most up-to-date therapeutics, based on molecular pathways of melanoma progression. Most recently, in his role with the Phase 1 Developmental Therapeutics Program, Dr. Hamid has been instrumental in bringing new therapies from the investigational lab to the clinic for patient benefit. These therapies involve immunological therapies such as PD-1 inhibitors, therapies against tumor angiogenesis, and targeted agents that block internal processes in tumor cell's function. These pathways change a normal cell into a cancerous one. Dr. Hamid's research focus involves manipulation of a patient's immune system to attack cancer cells and maintain continuously elevated levels of immunity and discovery of novel therapies for melanoma and other cancers that have spread to the central nervous system (brain and spine), an area that is historically difficult to treat.

    Dr. Hamid is recognized as a key opinion leader in melanoma therapeutics and treatment nationally and internationally. Through his role as the Chief of Immunotherapy and Translational Research patients at The Angeles Clinic have benefited from first in class, paradigm shifting drugs. Dr. Hamid was an investigator in the initial trials with Ipilimumab and Vemurafenib, both agents that led to significant survival benefits in the lives of our patients. Through his leadership the next phase of agents have been available to our patients. He has been a key investigator on combinations of BRAF/MEK inhibitors and novel immune therapy with PD-1 antibodies making them available for our patients.

    Dr. Hamid has presented research done at The Angeles Clinic at major national and international meetings including the American Society of Clinical Oncology, Society for Melanoma Research, and many other key national and international meetings. He has published manuscripts, abstracts, and reviews on immunotherapy, targeted therapy, and melanoma care in prestigious journals such as the Journal of Clinical Oncology (JCO), New England Journal of Medicine (NEJM), and Clinical Cancer Research.

    Dr. Hamid realizes that true benefit rests on fostering innovative therapies directly to the clinical trial format, the most effective a quickest way to ensure patients can benefit through therapy. Through his role as the Chief of Clinical Research, Dr. Hamid oversees a program that ensures all types and stages of melanoma patients have opportunity to benefit from therapy.

    You must be in to display playlists.

    Get a Dose of ReachMD in Your Inbox
    and Practice Smarter Medicine

    Stay current with the best in medical education.